Jennifer E. Miller, of the Edmond J. Safra Center for Ethics of Harvard, chats with Kevin Brewer of Astellas Pharma about the mission, ethics and reputational challenges of pharmaceutical companies. They conclude by discussing reform strategies.
In 2004, the Netherlands were shocked by the death of “Savanna.” Just a toddler, she was beaten to death by her parents. An investigation afterwards revealed that there appeared to be several signs and reports of child abuse in this case; however, it seemed that nobody had acted on them.
Today, there are two big stories that relate to the “institutional corruption” of medicine (aka conflicts of interests). For those who have been working long and hard on these issues, they are cause for hope. The needle does move.
Lorry drivers who regularly visited South and Eastern Europe were struck by the beauty and shapeliness of local women. This observation give rise to the “Edric Original” breast growth pill, filled with hop, the apparent key dietary difference between well-endowed Southern and Eastern European and everyone else (Scholtens, 1997). The full treatment will set you back €540—a bargain.
What is it about this offer that makes us doubt its credibility? Why do we evaluate some claims as more credible than others? Kim Hendrickx is currently finalizing a PhD thesis on the credibility of claims on food products. Bart Penders and Kim Hendrickx give a commented preview of the argument.
OTIThe new white paper from @OTI, @NewAmerica, & @HarvardEthics outlines the equity, privacy, and civil liberties risks posed by digital contact tracing tools, and the safeguards that policymakers can adopt to mitigate these concerns. t.co/rb6JObed47